FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, discusses how and why ...
ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability. Will Shrank, CEO ...
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene ...
Synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies ...
Building manufacturer partnerships depends on trust, data-driven insights, and integrated teams spanning market access, ...
In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement ...
In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US ...
While advances in cell & gene therapy continue to show promise for creating new treatments, this sector of the industry still ...
Sydni Johnston, Associate Director at Cardinal Health Sonexus™ Access and Patient Support, explains how manufacturers can ...
Advanced analytics are positioned to move hub operations from retrospective reporting to predictive identification of delay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results